Vermillion Signs Better Revenue-Splitting Deal with Quest for OVA1, Lowers Full-Year Sales Guidance

Despite a 74-percent increase in OVA1 test volume over the second quarter, company officials lowered their 2010 guidance from 8,000 to 10,000 OVA1 sales to a range of 5,000 to 5,500 sales for the year.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.